James Brown, MD
Ophthalmology · Starkville, MSNPI 1336231489
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Rxsight Inc at 50.8% of the total. Reporting peaked in 2022 at $4,645 and has fallen 89.7% since, to $477 in 2025. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $61.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$4K
- Alcon$2K
- Ivantis, Inc$592
- AbbVie$555
- Bausch & Lomb Americas Inc.$150
- Ocular Therapeutix, Inc.$131
- plus $522 from 12 others
What the payments were for
- Consulting fees$4,00048%
- Travel & lodging$4996%
- Food & beverage$3,81846%
- Gifts$451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 11 | $4,247 |
| Alcon | 50 | $2,165 |
| Ivantis, Inc | 18 | $592 |
| AbbVie(2 entities) | 25 | $555 |
| Bausch & Lomb Americas Inc. | 3 | $150 |
| Ocular Therapeutix, Inc. | 6 | $131 |
| Aerie Pharmaceuticals, Inc. | 6 | $104 |
| NEW World Medical,inc. | 4 | $85 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $85 |
| Glaukos Corporation | 2 | $65 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Davol Inc. | 1 | $30 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Eyepoint US, Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Sight Sciences, Inc. | 1 | $19 |
| Harrow Eye, LLC | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$4,000
- AcrySof$499
- Clareon$114
- STELLARIS$114
- LenSx$103
How this compares
$8,362 in reported general payments places this provider in the 90th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 94 | $79,985 |
| LumiganBimatoprost | 139 | $50,227 |
| Alphagan PBrimonidine Tartrate | 91 | $25,006 |
| XiidraLifitegrast | 20 | $15,818 |
| Brimonidine Tartrate | 267 | $15,775 |
| Cyclosporine | 28 | $10,584 |
| CombiganBrimonidine Tartrate/Timolol | 46 | $10,422 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 80 | $9,405 |
| RhopressaNetarsudil Mesylate | 25 | $8,483 |
| Prednisolone Acetate | 294 | $7,368 |
| TobradexTobramycin/Dexamethasone | 27 | $7,079 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $5,982 |
| Latanoprost | 890 | $4,737 |
| Brinzolamide | 21 | $2,763 |
| Timolol Maleate | 390 | $2,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $555 | $165,639370 claims |
| Bausch & Lomb Americas Inc.Xiidra | $150 | $15,81820 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $104 | $14,46640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Starkville
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
- Adam QuinnHattiesburg$29K
- Mark KoskoJackson$27K
- James ShippOxford$21K
- Calvin BrownOlive Branch$15K
- William AshfordMadison$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.